The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
Insulin pumps and CGMS provide greater flexibility, improved blood sugar control, and better quality of life for children and ...
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...
Agency Continues Efforts to Increase Access to Insulin Treatment Options SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S.
NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback